Al-Kassas R - Search Results

1

Development of a stability-indicating UPLC method for determination of isotretinoin in bulk drug.

Hsi SL, Surman P, Al-Kassas R. Hsi SL, et al. Among authors: al kassas r. Pharm Dev Technol. 2019 Feb;24(2):189-198. doi: 10.1080/10837450.2018.1454469. Epub 2018 Apr 12. Pharm Dev Technol. 2019. PMID: 29558234

2

Determination of pKa and forced degradation of the indoloquinoline antimalarial compound cryptolepine hydrochloride.

Kuntworbe N, Alany RG, Brimble M, Al-Kassas R. Kuntworbe N, et al. Pharm Dev Technol. 2013 Jul-Aug;18(4):866-76. doi: 10.3109/10837450.2012.668554. Epub 2012 Mar 22. Pharm Dev Technol. 2013. PMID: 22436019

3

Evaluation of degradation kinetics for abamectin in formulations using a stability indicating method.

Awasthi A, Razzak M, Al-Kassas R, Harvey J, Garg S. Awasthi A, et al. Acta Pharm. 2013 Mar;63(1):59-69. doi: 10.2478/acph-2013-0007. Acta Pharm. 2013. PMID: 23482313 Free article.

4

Development of mucoadhesive floating hollow beads of acyclovir with gastroretentive properties.

Svirskis D, Seyfoddin A, Chalabi S, In Kim JH, Langford C, Painter S, Al-Kassas R. Svirskis D, et al. Pharm Dev Technol. 2014 Aug;19(5):571-6. doi: 10.3109/10837450.2013.813539. Epub 2013 Jul 17. Pharm Dev Technol. 2014. PMID: 23859639

5

Development of gatifloxacin-loaded cationic polymeric nanoparticles for ocular drug delivery.

Duxfield L, Sultana R, Wang R, Englebretsen V, Deo S, Swift S, Rupenthal I, Al-Kassas R. Duxfield L, et al. Among authors: al kassas r. Pharm Dev Technol. 2016 Mar;21(2):172-9. doi: 10.3109/10837450.2015.1091839. Epub 2015 Oct 12. Pharm Dev Technol. 2016. PMID: 26794936

6

Separation and identification of degradation products in eprinomectin formulation using LC, LTQ FT-MS, H/D exchange, and NMR.

Awasthi A, Razzak M, Al-Kassas R, Greenwood DR, Harvey J, Garg S. Awasthi A, et al. J Pharm Biomed Anal. 2012 Apr 7;63:62-73. doi: 10.1016/j.jpba.2011.12.030. Epub 2012 Jan 28. J Pharm Biomed Anal. 2012. PMID: 22341479

7

Isolation and characterization of degradation products of moxidectin using LC, LTQ FT-MS, H/D exchange and NMR.

Awasthi A, Razzak M, Al-Kassas R, Greenwood DR, Harvey J, Garg S. Awasthi A, et al. Anal Bioanal Chem. 2012 Nov;404(8):2203-22. doi: 10.1007/s00216-012-6393-9. Epub 2012 Sep 18. Anal Bioanal Chem. 2012. PMID: 22986987

8

An overview on chemical derivatization and stability aspects of selected avermectin derivatives.

Awasthi A, Razzak M, Al-Kassas R, Harvey J, Garg S. Awasthi A, et al. Chem Pharm Bull (Tokyo). 2012;60(8):931-44. doi: 10.1248/cpb.c12-00258. Chem Pharm Bull (Tokyo). 2012. PMID: 22863694 Free article. Review.

9

Analytical profile of moxidectin.

Awasthi A, Razzak M, Al-Kassas R, Harvey J, Garg S. Awasthi A, et al. Profiles Drug Subst Excip Relat Methodol. 2013;38:315-66. doi: 10.1016/B978-0-12-407691-4.00007-1. Profiles Drug Subst Excip Relat Methodol. 2013. PMID: 23668407 Review.

10

Nanosizing techniques for improving bioavailability of drugs.

Al-Kassas R, Bansal M, Shaw J. Al-Kassas R, et al. J Control Release. 2017 Aug 28;260:202-212. doi: 10.1016/j.jconrel.2017.06.003. Epub 2017 Jun 8. J Control Release. 2017. PMID: 28603030 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

37 results

Search Page

Filters